Abstract:Abstract Background CRISPR-Cas9-based genome engineering represents a powerful therapeutic tool for cartilage tissue engineering and for understanding molecular pathways driving cartilage diseases. However, primary chondrocytes are difficult to transfect and rapidly dedifferentiate during monolayer (2D) cell culture, making the lengthy expansion of a single-cell-derived edited clonal population not feasible. For this reason, functional genetics studies focused on cartilage and rheumatic diseases have long been carried out in cellular models that poorly recapitulate the native molecular properties of human cartilaginous tissue (e.g., cell lines, induced pluripotent stem cells). Here, we set out to develop a non-viral CRISPR-Cas9, bulk-gene editing method suitable for chondrocyte populations from different cartilaginous sources. Methods We screened electroporation and lipid nanoparticles for ribonucleoprotein (RNP) delivery in primary polydactyly chondrocytes, and optimized RNP reagents assembly. We knocked out RELA (also known as p65), a subunit of the nuclear factor kappa B (NF-κB), in polydactyly chondrocytes and further characterized knockout (KO) cells with RT-qPCR and Western Blot. We tested RELA KO in chondrocytes from diverse cartilaginous sources and characterized their phenotype with RT-qPCR. We examined the chondrogenic potential of wild-type (WT) and KO cell pellets in presence and absence of interleukin-1β (IL-1β). Results We established electroporation as the optimal transfection technique for chondrocytes enhancing transfection and editing efficiency, while preserving high cell viability. We knocked out RELA with an unprecedented efficiency of ~90%, confirming lower inflammatory pathways activation upon IL-1β stimulation compared to unedited cells. Our protocol could be easily transferred to primary human chondrocytes harvested from osteoarthritis (OA) patients, human FE002 chondroprogenitor cells, bovine chondrocytes, and a human chondrocyte cell line, achieving comparable mean RELA KO editing levels using the same protocol. All KO pellets from primary human chondrocytes retained chondrogenic ability equivalent to WT cells, and additionally displayed enhanced matrix retention under inflamed conditions. Conclusions We showcased the applicability of our bulk gene editing method to develop effective autologous and allogeneic off-the-shelf gene therapies strategies and to enable functional genetics studies in human chondrocytes to unravel molecular mechanisms of cartilage diseases.

What problem does this paper attempt to address?

The paper attempts to address the issue of achieving efficient CRISPR-Cas9 gene editing in primary human chondrocytes. Specifically, the research team developed a non-viral, one-step CRISPR-Cas9 knockout strategy to enhance gene editing efficiency in primary chondrocyte populations from different sources. Due to the difficulty of transfecting primary chondrocytes and their rapid dedifferentiation during 2D culture, traditional single-cell derived clonal expansion methods are not feasible for these cells. To this end, the researchers optimized delivery methods such as electroporation and lipid nanoparticles (LNPs), and screened different RNP complex components, ultimately achieving efficient knockout of the RELA gene (a key subunit of the NF-κB pathway). This method not only improved editing efficiency but also maintained high cell viability and demonstrated reproducibility across various chondrocyte sources. This provides new tools for functional genetic studies and gene therapy of cartilage diseases.

Streamlined, single-step non-viral CRISPR-Cas9 knockout strategy enhances gene editing efficiency in primary human chondrocyte populations

Engineered Cartilage from Human Chondrocytes with Homozygous Knockout of Cell Cycle Inhibitor p21

Chondrocyte-specific genomic editing enabled by hybrid exosomes for osteoarthritis treatment

An Episomal CRISPR/Cas12a System for Mediating Efficient Gene Editing

Human fetal cartilage-derived chondrocytes and chondroprogenitors display a greater commitment to chondrogenesis than adult cartilage resident cells

Improved CRISPR/Cas9 gene editing in primary human myoblasts using low confluency cultures on Matrigel

High-Resolution Dissection of Chemical Reprogramming from Mouse Embryonic Fibroblasts into Fibrocartilaginous Cells

Exploration of CRISPR/Cas9-based gene editing as therapy for osteoarthritis

Non-viral Delivery of CRISPR–Cas9 Complexes for Targeted Gene Editing Via a Polymer Delivery System

Effect of passaging on bovine chondrocyte gene expression and engineered cartilage production

Compositional editing of extracellular matrices by CRISPR/Cas9 engineering of human mesenchymal stem cell lines

CRISPR-mediated Sox9 activation and RelA inhibition enhance cell therapy for osteoarthritis

Towards Clinical Translation of In Situ Cartilage Engineering Strategies: Optimizing the Critical Facets of a Cell-Laden Hydrogel Therapy

Peptide-mediated delivery of CRISPR enzymes for the efficient editing of primary human lymphocytes

Lipid Nanoparticle-Mediated Gene Editing of Human Primary T Cells and Off-Target Analysis of the CRISPR-Cas9 Indels

Long-term repair of porcine articular cartilage using cryopreservable, clinically compatible human embryonic stem cell-derived chondrocytes

Efficient gene knockout in primary human and murine myeloid cells by non-viral delivery of CRISPR-Cas9

Utilizing Codon Degeneracy in the Design of Donor DNA for CRISPR/Cas9-mediated Gene Editing to Streamline the Screening Process for Single Amino Acid Mutations.

Optimizing CRISPR/Cas9 Technology for Precise Correction of the Fgfr3-G374R Mutation in Achondroplasia in Mice

Expression of Chondrogenic Potential Markers in Cultured Chondrocytes from the Human Knee Joint

Allele-specific CRISPR/Cas9 editing inactivates a single nucleotide variant associated with collagen VI muscular dystrophy